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Background: Overdosed acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) causes severe liver injury.
We examined the effects of ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, on liver injury induced
by APAP overdose in mice.
Methods: Hepatotoxicity was induced to ICR male mice by an intraperitoneal injection with APAP (330 mg/kg). The
effects of ozagrel (200 mg/kg) treatment 30 min after the APAP injection were evaluated with mortality, serum
alanine aminotransferase (ALT) levels and hepatic changes, including histopathology, DNA fragmentation, mRNA
expression and total glutathione contents. The impact of ozagrel (0.001-1 mg/mL) on cytochrome P450 2E1
(CYP2E1) activity in mouse hepatic microsome was examined. RLC-16 cells, a rat hepatocytes cell line, were exposed
to 0.25 mM N-acetyl-p-benzoquinone imine (NAPQI), a hepatotoxic metabolite of APAP. In this model, the
cytoprotective effects of ozagrel (1–100 muM) were evaluated by the WST-1 cell viability assay.
Results: Ozagel treatment significantly attenuated higher mortality, elevated serum alanine aminotransferase levels,
excessive hepatic centrilobular necrosis, hemorrhaging and DNA fragmentation, as well as increase in plasma
2,3-dinor thromboxane B2 levels induced by APAP injection. Ozagrel also inhibited the hepatic expression of cell
death-related mRNAs induced by APAP, such as jun oncogene, FBJ osteosarcoma oncogene (fos) and C/EBP
homologous protein (chop), but did not suppress B-cell lymphoma 2-like protein11 (bim) expression and hepatic
total glutathione depletion. These results show ozagrel can inhibit not all hepatic changes but can reduce the
hepatic necrosis. Ozagrel had little impact on CYP2E1 activity involving the NAPQI production. In addition, ozagrel
significantly attenuated cell injury induced by NAPQI in RLC-16.
Conclusions: We demonstrate that the TXA2 synthase inhibitor, ozagrel, dramatically alleviates liver injury induced
by APAP in mice, and suggest that it is a promising therapeutic candidate for the treatment of APAP-induced
liver injury.Background
Acetaminophen (paracetamol, N-acetyl-p-aminophenol
[APAP]) is a widely used analgesic/antipyretic drug with
few side effects at therapeutic doses [1]. However, APAP
overdose produces hepatic injury, and is the most fre-
quent cause of acute liver failure in the United States [2],* Correspondence: y-zuka@gpo.kumamoto-u.ac.jp
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distribution, and reproduction in any mediumthe United Kingdom [3] and other countries [4,5]. APAP
preparations are often taken in excessive amounts for
suicide, and the consumption of multiple-drug prepara-
tions containing APAP may also cause severe liver dam-
age [6]. N-acetyl cysteine (NAC) is the only approved
drug for treating APAP overdose. However, NAC has
limited therapeutic efficacy against APAP hepatotoxicity.
Consequently, a novel treatment approach is required.
Liver injury induced by APAP overdose manifests as ex-
tensive centrilobular necrosis, infiltration of inflammatory
cells and bleeding. Massive production of cell death-
related markers, such as cytokeratin 18 [7] and hightral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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serum of patients with APAP-induced liver injury. Hepato-
cellular necrosis is initiated by a reactive metabolite, N-
acetyl-p-benzoquinone imine (NAPQI), mainly produced
by cytochrome P450 (CYP) 2E1 [9-12]. NAPQI likely
mediates injury via hepatic glutathione depletion, oxidative
and nitrosative stress, and inflammation. Furthermore, the
development and progression of liver injury induced by
APAP appears to involve multiple mediators, including re-
active oxygen species [13], peroxynitrite [14,15], cytokines
[16-19] and eicosanoids [20,21].
Eicosanoids, such as prostaglandins (PGs) and thrombox-
anes, play an important role in the development of various
diseases, as well as APAP hepatotoxicity [22-25]. North
et al. [21] and Cavar et al. [26] demonstrated that PGE2 has
a protective role in APAP-induced liver injury in zebrafish
and mice, respectively. PGI2 (prostacyclin) also seems to act
as a hepatoprotectant in APAP-induced liver injury [27]. In
addition, Reilly et al. [28] suggested that cyclooxygenase
(COX) 2-derived PGs, such as PGD2 and PGE2, have a
hepatoprotective function in APAP-induced liver injury in
mice. In contrast, thromboxane A2 (TXA2) seems to ex-
acerbate APAP hepatotoxicity. Ketoconazole, OKY-1581
and benzyl imidazole, which inhibit TXA2 production, are
able to prevent liver injury induced by APAP in rodents
[20,29]. These observations suggest that inhibiting TXA2
production is a promising strategy for the treatment of
liver injury due to APAP overdose. However, ketoco-
nazole, originally an antifungal agent, has side effects
caused by inhibition of CYPs [30]. In addition, while
OKY-1581 and benzyl imidazole are frequently used in
the laboratory, they are not approved for clinical use.
Therefore, the prospect for the clinical use of TXA2 syn-
thase inhibitors for the treatment of APAP-induced liver
injury is unclear.
Ozagrel (OKY-046; (E)-3-[4-(imidazol-1-ylmethyl)phenyl]
prop-2-enoic acid) was developed as a selective TXA2 syn-
thase inhibitor and has been widely used for treating
patients with bronchial asthma, and cerebral throm-
bosis and vasospasm in Japan [22,31,32]. Ozagrel allevi-
ates the symptoms of various diseases as assessed by
biochemical and clinical examination [22,23,31-33].
However, little has been reported on the effects of oza-
grel on APAP hepatotoxicity.
In this study, we examined whether ozagrel could pro-
tect against APAP-induced liver injury in mice. We
examined the effects of ozagrel on serum alanine ami-
notransferase (ALT) levels, mortality and histological
changes induced by APAP treatment. In addition, we
assessed hepatic glutathione content and the expression
of cell death-related markers in the APAP treated mice,
as well as CYP2E1 activity in mouse liver microsomes.
Furthermore, we investigated the effects of ozagrel on
NAPQI-induced hepatic injury in vitro.Methods
Reagents
Ozagrel hydrochloride monohydrate was kindly donated
by Ono Pharmaceutical CO., LTD. (Osaka, Japan) and
Kissei CO., Ltd. (Nagano, Japan). APAP, NAPQI and NAC
were purchased from Sigma-Aldrich (St. Louis, Missouri,
USA). Metaphosphoric acid was purchased from Alfa
Aesar (Ward Hill, Massachusetts, USA). Cell culture
reagents were obtained from GibcoW-Life Technologies
(Life Technologies Japan, Tokyo, Japan). HyClone™ fetal
bovine serum (FBS) was purchased from Thermo Scien-
tific (Logan, UT, USA). The cell counting kit and Cell-
stainW Double Staining Kit were obtained from Dojindo
Laboratories (Kumamoto, Japan). All other reagents and
solvents were of reagent grade. De-ionized and distilled
bio-pure grade water was used throughout the study.
Animal experiments
The APAP overdose-induced liver injury model was
based on a model previously reported by our group [34].
Male 7–9-week-old ICR mice (Charles River Laboratories
Japan INC., Yokohama, Japan) were used. Animals were
housed in cages in a room under controlled conditions at
24°C with a 12-h light cycle, and given free access to food
and water. Mice were fasted overnight, but given access to
water, prior to experiments. All experimental procedures
conformed to the animal use guidelines of the committee
for Ethics on Animal Experiments of Kumamoto Univer-
sity (approval numbers C23-269 and C22-172).
Mice were divided into the following groups: (1) vehicle
group, phosphate buffered saline (PBS) + saline treatment;
(2) APAP group, APAP (330 mg/kg) + saline treatment;
(3) APAP + ozagrel group, APAP (330 mg/kg) + ozagrel
(100 or 200 mg/kg) treatment; (4) APAP + NAC group,
APAP (330 mg/kg) + NAC (600 mg/kg). APAP was dis-
solved in warmed PBS (55°C). Ozagrel and NAC were dis-
solved in saline and administered intraperitoneally 30 min
after the APAP injection. Mice were euthanized 4 h after
APAP injection, and blood and liver samples were col-
lected. In the survival study, mice were monitored for 48 h
after the APAP injection.
Serum alanine transaminase level
Blood samples were collected from the inferior vena
cava and immediately centrifuged at 4000 × g at 4°C for
10 min, and sera were collected. Sera were stored
at −30°C until assay. Serum ALT levels were determined
using commercial assay kits (Wako Pure Chemical In-
dustries, Ltd., Osaka, Japan).
Hepatic histopathology
Liver tissue samples were fixed in 10% neutral buffered for-
malin and then embedded in paraffin. Microtome sections,
3-μm-thick, were prepared and stained with hematoxylin-
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modification of a previously reported method [35,36]. Ten
random fields for each section were analyzed by light mi-
croscopy. Liver injury was scored as follows: 0, no damage;
1, only a few fields affected; 2, zonal necrosis in most fields;
3, at least 3 foci of zonal necrosis in all fields; 4, centrilobu-
lar necrosis in most lobes in all fields; 5, panlobular conflu-
ent necrosis and hemorrhaging in all fields. In addition, to
evaluate hepatic cell death, terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining was
performed using the ApopTagW Peroxidase In Situ Apop-
tosis Detection Kit (Merck Millipore, Billerica, MA, USA)
as described in the manufacturer’s instructions.
Plasma 2,3-dinor thromboxane B2 level
Plasma samples were collected in ethylenediaminetetraa-
cetic acid containing blood collection tubes (Becton
Dickinson and Company Japan Inc., Tokyo, Japan) to
which indomethacin (10 μM) (Sigma) was added, and
centrifuged (3000 × g at 4°C for 10 min). Plasma level of
2, 3-dinor thromboxane B2 (2,3-dinor TXB2), a stable
metabolite of TXA2, was determined using enzyme im-
munoassay kit (Cayman, Michigan, USA) as described in
the manufacturer’s instructions.
Hepatic RNA isolation and quantitative real-time RT-PCR
analysis
Liver tissue samples were weighed and cooled, and stored
in liquid nitrogen until assay. To obtain total RNA, liver
samples were homogenized in TRIzolW reagent (Invitro-
gen™-Life Technologies Japan, Tokyo, Japan) according to
the manufacturer’s instructions. Quantitative real-time
RT-PCR for mouse Jun oncogene (Jun; NM_010591), FBJ
osteosarcoma oncogene (Fos; NM_010234), C/EBP hom-
ologous protein (Chop; NM_007837), B-cell lymphoma
2-like protein11 (Bim; NM_207680) and beta actin
(NM_007393) was carried out using the following pri-
mers: Jun sense, ATCCACGGCCAACATGCTC and
antisense, ACGTTTGCAACTGCTGCGTTAG; Fos
sense, TTACGCCAGAGCGGGAATG and antisense,
GTTCCCTTCGGATTCTCCGTTT; CHOP sense, AGC
TGGAAGCCTGGTATGAGGA and antisense, AGCT
AGGGACGCAGGGTCAA; Bim sense, CCGGAGATAC
GGATTGCACAG and antisense, CAGCCTCGCGGTA
ATCATTTG. Synthesis of cDNA from hepatic total RNA
was performed using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems-Life Technologies
Japan, Tokyo, Japan). Real-time PCR analysis was per-
formed on diluted cDNA samples with Fast SYBRW Green
master mix (Applied biosystems-Life Technologies Japan)
using StepOnePlus™ Real-time PCR system (Applied
biosystems-Life Technologies Japan). Melting curve ana-
lysis was performed for validation of specific amplification.
The relative quantity of target gene mRNA was normalizedagainst the beta actin level (internal control) and expressed
as fold induction.
Hepatic total glutathione content
The liver tissue samples were weighed and stored
at −80°C until assay. Tissue homogenates were prepared
in 5% metaphosphoric acid solution at a 1:5 (w/v) ratio
and centrifuged for 10 min at 1000 × g at 4°C. The
supernatant was collected and total GSH concentration
was measured using a BIOXYTECH GSH/GSSG-412
(OXIS Health Products, Inc, Portland, OR) according to
the manufacturer’s protocol. GSH content was expressed
as nmol/mg tissue.
CYP2E1 activity
CYP2E1 activity in mouse liver was examined using a
method previously reported by our laboratory with
minor modification [34]. In brief, a microsomal fraction
from the liver of the ICR mouse was prepared according
to a previously reported method [37]. CYP2E1 activity
was evaluated by conversion by the enzyme of the VividW
Blue Substrate (Invitrogen™-Life Technologies) into a
fluorescent metabolite. Microsomes from mouse liver,
NADPH-cytochrome P450 reductase, and cytochrome b5
and NADPH regeneration system were mixed and incu-
bated with or without varying concentrations of ozagrel
(0.001–1.0 mg/mL). The fluorescence intensity of the
probe at excitation and emission wavelengths of 409 and
460 nm, respectively, were measured using a fluorescence
microplate reader. CYP2E1 activity was then expressed as
the fluorescence intensity/mg protein.
Cell culture and measurements of cell viability
RLC-16 cells, a rat hepatocyte cell line, were purchased
from RIKEN BioResource Center (Ibaraki, Japan). Cells
were maintained under 5% CO2 and 95% air at 37°C in
MEM with 10% FBS, 100 IU/ml penicillin and 100 μg/mL
streptomycin. The cell injury induced by NAPQI was eval-
uated in accordance with methods described previously
[38,39]. In brief, RLC cells were seeded 1 × 104 cells/well
into a 96 well plate. After 24 h to allow cells to adhere,
the medium was replaced with fresh medium containing
250 μM NAPQI, with or without ozagrel (1–100 μM).
Cell viability was estimated 24 h after NAPQI addition by
measuring mitochondrial dehydrogenase activity with a
modified MTTassay, namely, the water-soluble tetrazolium
salt (WST-1) assay, using a kit (Dojindo Laboratories,
Kumamoto, Japan).
Statistical analysis
Results are expressed as mean ± S.E.M. Statistical ana-
lysis was performed using GraphPad Prism ver. 5.01
(GraphPad Software, San Diego, CA). Multiple compari-
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http://www.biomedcentral.com/1471-230X/13/21the results. When uniform variance of the result was
identified by Bartlett’s analysis (p < 0.05), one-way ana-
lysis of variance was used to test for statistical differ-
ences. When significant differences (p < 0.05) were
identified, the results were further analyzed by Dunnett’s
or Tukey’s multiple range test for significant differences
among the values. If uniform variance of the result was
not identified, non-parametric multiple comparisons were
made. After confirming significant differences (p < 0.05)
using Kruskal-Wallis analysis, the differences were then
examined by applying Dunnett’s test. Analysis of his-
tological score was also performed using these non-
parametric multiple comparison tests. As for comparisons
of two unpaired values, unpaired Student’s t-test was per-
formed. Survival data were analyzed using the Kaplan-
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Figure 1 Effects of ozagrel on serum ALT level and survival rate
in APAP-induced liver injury. (A) Serum ALT levels 4 h after the
APAP injection. Mice were treated with ozagrel (100 or 200 mg/kg),
NAC (600 mg/kg) or saline 30 min after the APAP (330 mg/kg)
injection. There was a significant increase in the APAP group (black
bar) compared with the vehicle group (white bar). The increase in
serum was significantly reduced by ozagrel (APAP + ozagrel group;
gray bar) and NAC (APAP + NAC group; hatched bar). Each bar
represents the mean ± S.E.M. (n = 5–7). *p < 0.01 compared with
the vehicle group, #p < 0.01 compared with the APAP group.
(B) Survival rate over a 48-h period in mice after APAP injection.
Mice were treated with ozagrel (200 mg/kg, n=5) or saline (n=11)
30 min after the APAP (330 mg/kg, n=16) injection. A significant
difference (p = 0.004) was observed between the APAP group and
the APAP + ozagrel group.Results
Effects on histological changes, elevation of serum ALT
level and survival rate induced by APAP injection in mice
We examined changes in ALT level in serum 4 h after
treatment with APAP (330 mg/kg), as a measure of
hepatic damage. APAP caused a significant increase in
serum ALT level compared with the vehicle group
(Figure 1A). In the APAP + ozagrel (100 or 200 mg/kg)
group, ALT level was significantly reduced compared
with the APAP group and the APAP + NAC (600 mg/kg)
group. ALT level (7.8 ± 1.4 IU/L) in the APAP + ozagrel
(200 mg/kg) group was similar to that (7.4 ± 2.4 IU/L) in
the vehicle group. As shown in Figure 1B, all mice died
within approximately 12 h after APAP injection. In
contrast, all of the mice in the APAP + ozagrel (200 mg/kg)
group survived.
Representative H&E staining of histological section is
shown in Figure 2. Severe centrilobular necrosis, hemor-
rhaging and hepatocyte degeneration were observed in
the APAP group. These pathological changes induced
by APAP were strongly suppressed in livers of mice in
the APAP + ozagrel (200 mg/kg) group. Minor hepatic
pathological changes were observed in the APAP + ozagrel
(100 mg/kg) group, though severe centrilobular necrosis
was observed in a single mouse. The histopathological
scores in the APAP + ozagrel (200 mg/kg) group were
significantly lower (p < 0.01) than in the APAP group
(Table 1).Changes in plasma 2, 3-dinor TXB2
As shown in Figure 3, plasma 2, 3-dinor TXB2 level was
significantly increased by injection of APAP, and the level
in the APAP group was approximately 5-fold greater than
in the vehicle group. An increase in 2, 3-dinor TXB2 level
was not observed in the APAP + ozagrel group.Effects on DNA fragmentation and hepatic mRNA
expression induced by APAP
To investigate the effects of ozagrel on nuclear DNA frag-
mentation, the TUNEL assay was performed, and to exam-
ine the expression of cell death-related genes, quantitative
real-time RT-PCR was performed for mouse liver Jun, Fos,
Chop and Bim transcripts. Representative TUNEL staining
is shown in Figure 4A. Numerous TUNEL-positive cells
APAP + ozagrel 100 mg/kg
APAP A
B
C APAP + ozagrel 200 mg/kg
Figure 2 Effect of ozagrel on hepatic histopathological changes
induced by APAP injection. Representative hepatic sections
stained with H&E are shown. Mice were treated with ozagrel
(100 or 200 mg/kg) or saline 30 min after the APAP (330 mg/kg)
injection. (A) APAP group; (B) APAP + ozagrel (100 mg/kg) group;
and (C) APAP + ozagrel (200 mg/kg) group. Scale bar: 100 μm.
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few positive cells were visible in the APAP + ozagrel group.
As shown in Figure 4B, APAP caused significant
increases in Jun, Fos, Chop and Bim mRNA expression
compared with vehicle treatment. The increases in Jun,
Fos and Chop expression induced by APAP were inhib-
ited by ozagrel (200 mg/kg), while Bim expression was
not attenuated.
Changes in liver glutathione content and CYP 2E1 activity
in hepatic microsomes
To examine the mechanisms underlying the protective
effect of ozagrel against APAP-induced liver injury, hep-
atic GSH consumption and mouse CYP 2E1 activity
were assessed. As shown in Figure 5A, hepatic total
GSH level 2 and 4 h after APAP injection were signifi-
cantly decreased in all groups compared with the value
at 0 h. No significant difference was observed between
these values in the APAP group and the APAP + ozagrel
group. In contrast, the APAP + NAC group had signifi-
cantly higher GSH levels compared with the APAP and
APAP + ozagrel groups at 2 h.
The results of the in vitro CYP2E1 activity assay are
shown in Figure 5B. Ozagrel, at any dose (0.001–1.0 mg/
mL), did not inhibit CYP2E1 activity.
Protective effect against NAPQI-induced cell death
As shown in Figure 6, RLC-16 cells treated with 250 μM
NAPQI for 24 h showed an approximately 50% decrease
in cell viability. When 1–100 μM ozagrel was added to the
culture medium immediately after NAPQI exposure, the
decrease in cell viability was significantly inhibited in a
dose-dependent manner. Treatment with NAC (1 mM)
also significantly attenuated the reduction in cell viability
(Figure 6).
Discussion
We demonstrated that the APAP-induced increases in
serum ALT and plasma 2,3-dinor TXB2 levels, as well as
the rise in mortality rate, were drastically attenuated by
ozagrel, a selective TXA2 synthase inhibitor, adminis-
tered 30 min after the APAP injection. In addition, the
histopathological changes produced by APAP were also
suppressed by ozagrel. These results indicate that oza-
grel protects against hepatotoxicity induced by APAP.
The protective effect of ozagrel was comparable to that
of NAC, the sole antidote for APAP hepatotoxicity.
A number of animal studies have demonstrated that
ozagrel is protective against various forms of trauma and
disease, including lung injury [23,33], bronchial asthma
[22,40] and ischemia/reperfusion-induced organ injury
[41,42]. Ozagrel promptly inhibits TXA2 synthase in vitro
and in vivo [31]. In our previous study, we demonstrated
that ozagrel protects against acute lung injury induced by
Table 1 Histopathological scores in mice treated with ozagrel 30 min after APAP (330 mg/kg) injection
Treatment Histological scores (4 h after the APAP injection)
0 1+ 2+ 3+ 4+ 5+
APAP + saline 0 0 0 2 1 2
APAP + ozagrel 100 mg/kg 2 0 2 0 0 1
APAP + ozagrel 200 mg/kg 4 1 0 0 0 0
Mice were treated with ozagrel (100 or 200 mg/kg) or saline 30 min after the APAP (330 mg/kg) injection. Hepatic sections from mice 4 h after APAP injection
were scored according to severity of injury: 0, no damage; 1, only a few fields affected; 2, zonal necrosis in most fields; 3, at least 3 foci of zonal necrosis in all
fields; 4, centrilobular necrosis in most lobes in all fields; 5, panlobular confluent necrosis and hemorrhaging in all fields. Values represent the total number of
mice given each score (n = 5).
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was protective despite being administered 60 min after
APAP injection (Additional file 1: Figure 1S). From a clin-
ical perspective, a drug that has efficacy when adminis-
tered after the initiating insult has tremendous therapeutic
potential.
Various inflammatory mediators are thought to be
involved in the development of liver injury induced by
APAP [19], and TXA2 appears to be one of these
[20,29]. In this study, we observed a significant increase
in plasma 2,3-dinor TXB2 levels following APAP injec-
tion, which is in agreement with previous reports. Reilly
et al. (2001) [28] observed significantly elevated APAP-

























Figure 3 Effect of ozagrel on plasma 2,3-dinor TXB2 levels in
APAP-induced liver injury. Mice were treated with ozagrel
(200 mg/kg) or saline 30 min after the APAP (330 mg/kg) injection.
Plasma 2,3-dinor TXB2 levels were measured by enzyme
immunoassay 4 h after the APAP injection. There was a significant
increase in plasma 2,3-dinor TXB2 in the APAP group (black bar)
compared with the vehicle group (white bar). The increase was
significantly suppressed by ozagrel (the APAP + ozagrel group; gray
bar). Each value represents the mean ± S.E.M. (n = 6). **p < 0.01.mice treated with a COX-2 inhibitor. These authors sug-
gested that eicosanoids, such as PGE and PGI2, have an
important hepatoprotective function, and that COX in-
hibition may exacerbate APAP-induced liver injury.
However, the excessive production of 2,3-dinor TXB2
induced by APAP and the protective effects of ozagrel
observed in this study suggest that TXA2 is an aggravat-
ing factor in APAP-mediated hepatotoxicity.
Jun and Fos have been reported to be associated with
the degree of APAP-induced liver injury [43,44]. In this
study, ozagrel significantly suppressed the APAP-induced
elevation in hepatic Jun and Fos mRNA expression. This
result provides further support for a hepatoprotective
function for ozagrel. In addition, APAP significantly
induced expression of Chop and Bim mRNA, both of
which play important roles in cell death during endoplas-
mic reticulum stress in various diseases. Nagy et al. (2007)
[45] observed DNA fragmentation and CHOP induction
in the livers of APAP-treated mice. We demonstrated that
ozagrel attenuates the increase in the number of TUNEL-
positive cells and suppresses the elevation in Chop mRNA
expression induced by APAP in the liver. However, ozagrel
did not repress the APAP-mediated increase in Bim
mRNA expression. Badmann et al. (2011) [46] reported
that Bim-deficient mice were substantially protected from
APAP-induced liver damage, and suggested that Bim plays
an important role in the development of liver injury
induced by APAP. In cell death-related processes, the Bim
pathway seems to be regulated not only by the transcrip-
tional activation of Bim [46] but also by other mechan-
isms, such as phosphorylation or proteasomal degradation
of Bim protein [47] and binding to anti-apoptotic mole-
cules, including Bcl-2 and Bcl-XL [48]. Therefore, the
effects of ozagrel on the Bim pathway remain unclear, and
further study is needed to fully elucidate the effects of the
drug. In this context, our finding that ozagrel does not
affect APAP-induced Bim mRNA expression (in contrast
to Chop, Jun and Fos mRNAs) is interesting and provides
insight into the mechanisms underlying the protective ef-
fect of ozagrel against APAP hepatotoxicity.
The hepatotoxicity of APAP is triggered by a reactive














































Figure 4 Effects of ozagrel on hepatic cell death-related markers in liver induced by APAP injection. The effects of ozagrel on DNA
fragmentation (A) and cell death-related gene expression (B) in liver induced by APAP injection. Mice were treated with ozagrel (200 mg/kg) or
saline 30 min after the APAP (330 mg/kg) injection. The liver tissue samples were collected 4 h after the APAP injection. (A) Representative TUNEL
staining. A significant number of brown TUNEL-positive cells were observed in the APAP group, while only a few brown cells were observed in
the APAP + ozagrel group. (B) Changes in mRNA levels of Jun, Fos, chop and Bim in liver were analyzed by quantitative real-time RT-PCR. There
were significant increases in the relative expression levels of all of these genes in the APAP group (black bar) compared with the vehicle group
(white bar). The increases in Jun, Fos and chop mRNA levels, but not that of Bim mRNA, were significantly reduced by ozagrel (APAP + ozagrel
group; gray bar). Each value represents the mean ± S.E.M. (n = 5–6). *p < 0.05, **p < 0.01.
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http://www.biomedcentral.com/1471-230X/13/21[9-12]. Jaeschke et al. (2012) [19] and Bantel and Schulze-
Osthoff (2012) [49] found that excessive NAPQI produc-
tion depletes the hepatic GSH, and that this process is
critical for the initiation of APAP hepatoxicity. In this study,
ozagrel did not significantly attenuate the reduction in hep-
atic GSH content induced by APAP. In addition, ozagrel
did not inhibit CYP2E1 activity in liver microsomes. Theseresults suggest that the protective effect of ozagrel against
APAP-induced hepatic injury is not due to inhibition of
NAPQI production. This notion is supported by the
in vitro results showing that ozagrel attenuates cellular in-
jury induced by NAPQI in the RLC-16 hepatocyte cell line.
These results suggest that the target of ozagrel, TXA2 syn-
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Figure 5 Effects of ozagrel on hepatic GSH depletion induced
by APAP and CYP 2E1 level. (A) Mice were treated with ozagrel
(200 mg/kg), NAC (600 mg/kg) or saline 30 min after the APAP
(330 mg/kg) injection. The liver tissue samples were collected 0,
2 and 4 h after the APAP injection. Significant decreases in hepatic
total GSH level were observed in all groups. The GSH level of APAP +
NAC group was significantly higher than that of APAP group and
APAP + ozagrel group at 2 h. Each value represents the mean ± S.E.M.
(n = 4–5). *p < 0.001 compared with the 0 h group. #p < 0.001
compared with the APAP group and APAP + ozagrel group. (B) CYP
2E1 level in mouse hepatic microsomes was evaluated using a
fluorogenic probe, the VividW CYP2E1 Blue Substrate. Ozagrel at
various concentrations (0.001–1.0 mg/mL) was incubated with the
reaction mixture and the fluorescence intensity of the fluorescent
metabolite was measured. Each value represents the mean ± S.E.M.




























Figure 6 The effect of ozagrel on cell viability reduced by
NAPQI in RLC-16 cells. Cells were exposed to 250 μM NAPQI in
either the presence or absence of ozagrel (1–100 μM) or NAC
(1 mM). Cell viability was measured 24 h after the NAPQI exposure
using the WST-1 assay. NAPQI (black bar) induced a decrease in cell
viability. This reduction was significantly inhibited by ozagrel
(gray bar) and NAC (hatched bar). Each bar represents the mean ± S.
E.M. (n = 4). *p < 0.01 compared with the APAP group.
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APAP-induced liver injury. However, further detailed study
(e.g., using TXA2 receptor knockout mice and TXA2 syn-
thase knockdown) is required to fully uncover the roles of
TXA2 in APAP hepatotoxicity.
OKY-1581 ((E)-2-methyl-3-[4-(pyridin-3-ylmethyl)phenyl]
prop-2-enoic acid) was discovered as a selective inhibitor
of TXA2 synthase, along with ozagrel, and shows protective
effects against APAP hepatotoxicity in mice [29]. However,
the development of clinical OKY-1581 formulations has
been abandoned because of adverse reactions observed inclinical trials. In comparison, ozagrel was found to be an
ideal compound for use as a highly selective TXA2 synthase
inhibitor [31], and it is in clinical usein Japan. Although
further studies to evaluate the usefulness and safety of oza-
grel in patients with APAP hepatotoxicity are needed, the
results of this study suggest that the inhibition of TXA2
synthase by the drug is effective for the treatment of
APAP-induced liver injury.
NAC is clinically used as an antidote for APAP intoxi-
cation, and it is thought that NAC provides cysteine,
which is a precursor of GSH (which traps NAPQI), lead-
ing to a decrease in toxicity [16,50]. In this study, NAC
increased hepatic GSH content 2 h after the APAP injec-
tion and significantly prevented cell injury induced by
NAPQI in RLC-16 cells. These results indicate that
NAC provides GSH and detoxifies NAPQI. In compari-
son, although ozagrel exerted a remarkable hepatopro-
tective action against APAP-induced liver injury in mice,
GSH content 2 h after APAP injection was not increased
by the drug. These results indicate that ozagrel has a
mode of action different from that of NAC in protection
against APAP hepatotoxicity. For the development of
new therapeutic strategies, it is interesting that ozagrel
has a mechanism of action distinct from that of an exist-
ing agent, NAC.
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lar injury induced by NAPQI in RLC-16 cells was less
robust than that of NAC, it may not indicate the infer-
iority of ozagrel as a therapeutic agent for APAP hepato-
toxicity. The in vitro model of APAP hepatotoxicity
using the cell culture system does not seem to fully
agree with the in vivo model. For example, although the
c-Jun N-terminal kinase inhibitor SP600125 drastically
attenuates APAP-induced liver injury in the in vivo
model, it has little effect in an in vitro model [44,51].
Therefore, the in vitro model of APAP hepatotoxicity may
not be adequate for comparison of the efficacy of drugs.
Nonetheless, it may provide insight into the mechanisms
underlying the protective effect of the agents against
APAP liver injury. If ozagrel protects against APAP-
induced liver injury only through the modulation of in-
flammatory cell activity, such as inhibition of neutrophils
or Kupffer cells, it would not be able to exert a protective
action in an in vitro model. Therefore, the results of the
in vitro model demonstrate that ozagrel, at least in part,
protects against APAP hepatotoxicity by inhibiting the
oncotic necrosis of hepatocytes.
Conclusion
In summary, we demonstrate that the TXA2 synthase in-
hibitor ozagrel strikingly ameliorates liver injury induced
by APAP in mice. We suggest that ozagrel is a promising
candidate for the treatment of hepatotoxicity due to ac-
cidental or intentional APAP overdose.
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